<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Albumin solution: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Albumin solution: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Albumin solution: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11033" href="/d/html/11033.html" rel="external">see "Albumin solution: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13277" href="/d/html/13277.html" rel="external">see "Albumin solution: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F130903"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Albuked 25;</li>
<li>Albuked 5;</li>
<li>Albumin-ZLB;</li>
<li>Albuminex;</li>
<li>AlbuRx;</li>
<li>Albutein;</li>
<li>Flexbumin;</li>
<li>Human Albumin Grifols [DSC];</li>
<li>Kedbumin;</li>
<li>Plasbumin-25;</li>
<li>Plasbumin-5</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865575"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Alburex-25;</li>
<li>Alburex-5;</li>
<li>Octalbin;</li>
<li>Plasbumin-5</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F130921"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Blood Product Derivative;</li>
<li>
                        Plasma Volume Expander, Colloid</li></ul></div>
<div class="block doa drugH1Div" id="F130906"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Use <b>5%</b> solution in hypovolemic patients or intravascularly depleted patients. Use <b>25%</b> solution in patients in whom fluid and sodium intake is restricted or to mobilize fluids.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dose:</b>
<b>IV:</b> 25 g; initial dose may be repeated in 15 to 30 minutes if response is inadequate.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b246fd55-f7fb-42b1-83b1-963ff8c0d8b0">Adult respiratory distress syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adult respiratory distress syndrome:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Although listed in manufacturer's labeling, impact on major clinical outcome data (eg, mortality) is limited and the potential benefit remains to be seen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31258917','lexi-content-ref-12394941','lexi-content-ref-16096441','lexi-content-ref-24405693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31258917','lexi-content-ref-12394941','lexi-content-ref-16096441','lexi-content-ref-24405693'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">25% albumin: <b>IV:</b> 25 g over 30 minutes (in combination with furosemide); may repeat at 8 hours (if necessary) for 3 days; titrate to fluid loss and normalization of serum total protein. Patients enrolled into the clinical trial had hypoproteinemia (total protein &lt;6 g/dL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16096441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16096441'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="275cb8ab-bbe4-4423-8d25-ef0b06608589">Cirrhotic ascites, therapeutic large volume paracentesis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cirrhotic ascites, therapeutic large volume paracentesis (adjunctive agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">25% albumin: <b>IV:</b> 6 to 8 g for every liter removed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-33067334']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-33067334'])">Ref</a></span>) <b>or</b> 50 g total for paracentesis &gt;5 L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15563641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15563641'])">Ref</a></span>). <b>Note:</b> Administer at the time of or soon after the procedure to avoid postparacentesis complications (eg, hypovolemia, hyponatremia, kidney impairment) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-33067334']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-33067334'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27acc44a-54f0-4ab9-ba10-5b0a383312c4">Hepatorenal syndrome type 1 or acute kidney injury in cirrhosis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatorenal syndrome type 1 or acute kidney injury in cirrhosis, treatment (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Used before or in combination with norepinephrine, terlipressin, or midodrine plus octreotide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-33657294']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-33657294'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">25% albumin: <b>IV:</b> Initial: 1 g/kg daily for 2 days (maximum: 100 g/day), followed by 20 to 50 g daily until clinical outcome is achieved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-10347109','lexi-content-ref-26896734','lexi-content-ref-25644760','lexi-content-ref-33837624','lexi-content-ref-23463403','lexi-content-ref-33657294']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-10347109','lexi-content-ref-26896734','lexi-content-ref-25644760','lexi-content-ref-33837624','lexi-content-ref-23463403','lexi-content-ref-33657294'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="37991dd3-af03-4bcc-b499-c5b1251a83c6">Hypovolemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypovolemia:</b>
<b>Note:</b> For replacement of volume deficit, 5% albumin is generally preferred.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 12.5 to 25 g (250 to 500 mL); repeat after 15 to 30 minutes as needed (if hemodynamic stability is not achieved). <b>Note:</b> In patients with sepsis or septic shock, may consider after inadequate response to large volumes of crystalloid therapy. The volume administered and the rate of infusion should be adapted to individual response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34605781']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34605781'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e16e7a44-cd53-4f4e-948d-cdafd8df4419">Ovarian hyperstimulation syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian hyperstimulation syndrome (treatment):</b> 25% albumin: <b>IV:</b> 50 to 100 g over 4 hours; repeat at 4 to 12 hours intervals as needed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f15ec906-79ff-4bd7-9ca7-cf8083e2f195">Plasma exchange, therapeutic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plasma exchange, therapeutic:</b> 5% albumin: <b>IV:</b> Titrate dose to plasma volume removed during procedure.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5753b930-8bad-462f-9c65-900e92275bf5">Spontaneous bacterial peritonitis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spontaneous bacterial peritonitis, treatment (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Some experts reserve for patients with existing kidney or severe hepatic impairment (eg, creatinine &gt;1 mg/dL, BUN &gt;30 mg/dL, or bilirubin &gt;4 mg/dL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Runyon.3','lexi-content-ref-17369392','lexi-content-ref-10432325']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Runyon.3','lexi-content-ref-17369392','lexi-content-ref-10432325'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">25% albumin: <b>IV:</b> Initial: 1.5 g/kg within 6 hours of diagnosis in combination with appropriate antimicrobial therapy, followed by 1 g/kg on day 3 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-22980594','lexi-content-ref-17369392','lexi-content-ref-10432325']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-22980594','lexi-content-ref-17369392','lexi-content-ref-10432325'])">Ref</a></span>); a possible alternative dose is 1 g/kg once daily for 2 days but it is not well studied (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342'])">Ref</a></span>). While the maximum albumin dose varies in clinical practice, some suggest not exceeding 100 g per dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22980594']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22980594'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991290"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (large molecular weight of 66 kDa): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (large molecular weight): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988604"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doe drugH1Div" id="F130907"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F130915"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13277" href="/d/html/13277.html" rel="external">see "Albumin solution: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Albumin <b>5%</b> should be used in hypovolemic or intravascularly depleted patients; albumin <b>25%</b> should be used in patients with fluid or sodium restrictions (eg, patients with hypoproteinemia and generalized edema, or nephrotic syndrome). Dose depends on condition of patient.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="53e70cc0-1402-46af-9e43-8f03cd681d0a">Ascites with hypoalbuminemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ascites with hypoalbuminemia:</b> Limited data available: Infants, Children, and Adolescents: 25% albumin: IV: 0.5 to 1 g/kg/dose over 2 to 3 hours; may repeat up to 3 times per day until albumin is &gt;2.5 g/dL; maximum dose: 25 g/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21464748','lexi-content-ref-26325252','lexi-content-ref-12734047']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21464748','lexi-content-ref-26325252','lexi-content-ref-12734047'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="17ced2ec-520d-41d8-b58d-c920d7594421">Hypovolemia, plasma volume expansion, including hypovolemic shock</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypovolemia, plasma volume expansion, including hypovolemic shock:</b> Infants, Children, and Adolescents: 5% albumin: IV: 0.5 to 1 g/kg/dose (10 to 20 <b>mL</b>/kg/dose) over 5 to 10 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23353941','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23353941','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note</b>: Usual adult dose: 12.5 to 25 g/dose (250 to 500 <b>mL</b>/dose). May repeat after 15 to 30 minutes if response is not adequate.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5b170c89-29da-45b6-9255-9410a43290db">Large volume paracentesis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Large volume paracentesis:</b> Limited data available: Infants, Children, and Adolescents: 5% or 25% albumin: IV: 0.5 to 1 g/kg over 1 to 2 hours after paracentesis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21464748','lexi-content-ref-11593116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21464748','lexi-content-ref-11593116'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="be5f7233-7aec-43f3-8fe2-6553d21646fe">Nephrotic syndrome edema, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nephrotic syndrome edema, refractory:</b> Infants, Children, and Adolescents: 25% albumin: IV: 0.5 to 1 g/kg/dose over 30 to 60 minutes followed by diuretic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1','lexi-content-ref-12921248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1','lexi-content-ref-12921248'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51063629"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosing adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51063630"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosing adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F130882"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing, heart failure, hypotension, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, rigors</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, dyspnea, pulmonary edema</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, atrial fibrillation</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperchloremic metabolic acidosis (Ritzenthaler 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia, sialorrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis (Lozano 2019), hypersensitivity reaction (including severe hypersensitivity reaction), nonimmune anaphylaxis (Fujita 2007), type 1 hypersensitivity reaction (Wang 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Febrile reaction</p></div>
<div class="block coi drugH1Div" id="F130894"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to albumin or any component of the formulation; severe anemia, heart failure; patients at risk of volume overload (eg, patients with kidney insufficiency, severe anemia, stabilized chronic anemia, or heart failure); dilution with sterile water for injection (may cause hemolysis or acute kidney failure).</p></div>
<div class="block war drugH1Div" id="F130880"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Severe allergic or anaphylactic reaction may occur. Discontinue immediately and manage appropriately if allergic or anaphylactic reactions are suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Coagulation abnormality: Large replacement volumes may result in coagulation abnormality. Monitor and replete with blood constituents if indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte imbalance: Large replacement volumes may result in electrolyte imbalance. Monitor electrolytes and replace or maintain as indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemodynamic effects: Cardiac or respiratory failure, kidney failure, or increasing intracranial pressure can occur; closely monitor hemodynamic parameters in all patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypervolemia/hemodilution: Use with caution in conditions where hypervolemia and its consequences or hemodilution may increase the risk of adverse effects (eg, heart failure, pulmonary edema, hypertension, hemorrhagic diathesis, cirrhosis, esophageal varices). Adjust rate of administration per hemodynamic status and solution concentration; monitor closely with rapid infusions. Avoid rapid infusions in patients with a history of cardiovascular disease (may cause volume overload and pulmonary edema). Discontinue at the first signs of cardiovascular overload (eg, headache, dyspnea, jugular venous distention, rales, abnormal elevations in systemic or central venous BP). All patients should be observed for signs of hypervolemia, such as pulmonary edema. Monitor BP.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Critical illness: Avoid use for resuscitation in patients with traumatic brain injury due to increased mortality when used in this population (Myburgh 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; protein load may exacerbate or precipitate encephalopathy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution in patients with kidney impairment; protein load may precipitate azotemia. Patients with chronic kidney insufficiency receiving albumin solution may be at risk for accumulation of aluminum and potential toxicities (eg, hypercalcemia, vitamin D refractory osteodystrophy, anemia, severe progressive encephalopathy).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium restricted patients: Use with caution in those patients for whom sodium restriction is necessary. Albumin 5% and 25% solutions contain 130 to 160 mEq/L sodium and are considered isotonic with plasma.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aluminum: The parenteral product may contain aluminum (Kelly, 1989); toxic aluminum concentrations may be seen with high doses, prolonged use, or kidney dysfunction. Premature neonates are at higher risk due to immature kidney function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dilution: Do not dilute 5% albumin with sterile water for injection (may result in hemolysis and/or kidney failure).</p>
<p style="text-indent:-2em;margin-left:4em;">• Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: Packaging may contain natural latex rubber.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878315"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In neonates, use the 25% concentration with extreme caution due to risk of intraventricular hemorrhage (from rapid expansion of the intravascular volume); infuse slowly.</p>
<p style="text-indent:0em;margin-top:2em;">Due to the occasional shortage of 5% human albumin, 5% solutions may at times be prepared by diluting 25% human albumin with NS or with D5W (if sodium load is a concern); however, do not use sterile water to dilute albumin solutions, as this may result in hypotonic-associated hemolysis which can be fatal.</p></div>
<div class="block foc drugH1Div" id="F130890"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Albumin-ZLB: 5% (250 mL, 500 mL); 25% (50 mL, 100 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25% (50 mL, 100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Albuked 5: 5% (250 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Albuked 25: 25% (50 mL, 100 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Albuminex: 5% (250 mL, 500 mL); 25% (50 mL, 100 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">AlbuRx: 5% (250 mL, 500 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Albutein: 5% (50 mL, 250 mL, 500 mL); 25% (20 mL, 50 mL, 100 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Flexbumin: 5% (250 mL); 25% (50 mL, 100 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Human Albumin Grifols: 25% (50 mL [DSC], 100 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kedbumin: 25% (50 mL, 100 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Plasbumin-5: 5% (50 mL, 250 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Plasbumin-25: 25% (20 mL, 50 mL, 100 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5% (100 mL, 250 mL, 500 mL); 25% (50 mL, 100 mL)</p></div>
<div class="block geq drugH1Div" id="F130876"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16322967"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Albuked 25 Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25% (per mL): $1.15</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Albuked 5 Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per mL): $0.23</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Albumin Human Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per mL): $0.33</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25% (per mL): $1.38 - $2.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Albuminex Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per mL): $0.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25% (per mL): $1.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Albutein Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per mL): $0.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25% (per mL): $1.12</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Flexbumin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per mL): $1.39</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25% (per mL): $1.39</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Human Albumin Grifols Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25% (per mL): $2.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Plasbumin-25 Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25% (per mL): $1.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Plasbumin-5 Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per mL): $0.78</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865576"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alburex-5: 5% (100 mL, 250 mL, 500 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alburex-25: 25% (50 mL, 100 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Plasbumin-5: 5% (50 mL, 250 mL, 500 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5% (50 mL, 100 mL, 250 mL, 500 mL); 25% (50 mL, 100 ea, 100 mL)</p></div>
<div class="block adm drugH1Div" id="F130892"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> For IV administration only. <b>Note:</b> Some products may require a filter; refer to product labeling. Rate of infusion is dependent upon use and clinical condition. See indication for specific rates in dosing or refer to institutional protocol. Too rapid infusion may result in volume overload. In emergencies, may administer as rapidly as necessary to improve clinical condition.</p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer's recommended maximum administration rates:</p>
<p style="text-indent:-2em;margin-left:6em;">5%, 25%: Typically, not recommended to exceed 1 to 2 mL/minute in patients without shock.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Albumin 25% may be given undiluted or diluted in normal saline. May give in combination or through the same administration set as saline or carbohydrates. Warm to room temperature before use if large volumes are administered. Use within 4 hours after entering package; discard unused portion. Do not use with ethanol or protein hydrolysates (precipitation may form).</p></div>
<div class="block admp drugH1Div" id="F52612189"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: <b>Note: </b>Some products may require a filter; refer to product labeling. Rate of infusion is dependent upon use and clinical condition. See indication-specific rates in dosing or refer to institutional protocol. Too rapid infusion may result in vascular overload. In emergencies, may administer as rapidly as necessary to improve clinical condition.</p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer recommended maximum administration rates:</p>
<p style="text-indent:-2em;margin-left:6em;">5%: Do not exceed 1 mL/minute in patients with normal plasma volume (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">25%: Do not exceed 1 to 2 mL/minute in patients without shock (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F130891"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute respiratory distress syndrome (25% solution only):</b> To correct interstitial pulmonary edema (in combination with diuretics) and hypoproteinemia associated with acute respiratory distress syndrome.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cirrhotic ascites, therapeutic large volume paracentesis (adjunctive agent):</b> To maintain intravascular volume following removal of large-volume paracentesis in cirrhotic patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypovolemia:</b> Plasma volume expansion and maintenance of intravascular volume in select patients for the treatment of hypovolemia (with or without shock). For replacement of volume deficit, 5% solution is generally preferred.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Neonatal hemolytic disease:</b> Binds and detoxifies unconjugated bilirubin in severe hemolytic disease of the newborn during exchange transfusion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nephrosis (acute) (adjunctive agent):</b> Treatment of edema in patients with acute nephrosis in combination with diuretics.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian hyperstimulation syndrome, treatment (25% solution only):</b> As a plasma volume expander in fluid management for the treatment of severe ovarian hyperstimulation syndrome.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Plasma exchange, therapeutic:</b> To avoid excessive hypoproteinemia, during certain types of exchange transfusion, or with the use of very large volumes or previously frozen or washed red cells.</p></div>
<div class="block off-label drugH1Div" id="F25720703"><span class="drugH1">Use: Off-Label: Adult</span><p>Hepatorenal syndrome type 1 or acute kidney injury in cirrhosis, treatment; Spontaneous bacterial peritonitis, treatment</p></div>
<div class="block mst drugH1Div" id="F130929"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Albutein may be confused with albuterol.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298693"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F130884"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F56764405"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Albumin may be used for the treatment of severe ovarian hyperstimulation syndrome (OHSS) when hydration with NS is insufficient to achieve or maintain hemodynamic stability and urine output. Available data are insufficient to recommend use of albumin to reduce the risk OHSS in patients undergoing controlled ovarian stimulation (ASRM 2016; SOGC [Shmorgun 2017]).</p></div>
<div class="block pri drugH1Div" id="F13334387"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Albumin is an endogenous substance; products are prepared from pooled human plasma. Use in pregnant patients may be considered when contraindications to nonprotein colloids exist (Liumbruno 2009).</p></div>
<div class="block brc drugH1Div" id="F13334388"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Endogenous albumin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F2885289"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;text-align:justify;display:inline">Some products may contain potassium and/or sodium.</p></div>
<div class="block mop drugH1Div" id="F130888"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor electrolytes, hemoglobin/hematocrit, and urine output regularly; monitor hemodynamic parameters, BP, heart rate, volume status, and signs and symptoms of pulmonary edema, central venous pressure, pulmonary artery occlusion pressure.</p></div>
<div class="block pha drugH1Div" id="F130879"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Provides increase in intravascular oncotic pressure and causes mobilization of fluids from interstitial into intravascular space</p></div>
<div class="block phk drugH1Div" id="F45653130"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;">Half-life: 15 to 20 days</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F130897"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Albiomin | Albuman | Human Albumin | Human albumin biotest</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Albumina humana | Albumina serica humana unc | Albunorm | Alburex | Albutein | Buminate | Flexbumin | Uman albumin | Zenalb</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Albiomin | Albunorm | Alburex | Crealb | Flexbumin | Human Albumin | Humanalbumin | Humanalbumin haemo | Humanalbumin Kedrion</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Albuman | Albumine human aventis behring | Albumine human aventis p.mer.msd | Albumine human croix rouge | Albumine human immuno | Albunorm | Alburex | Flexbumin | Hibumine | Octalbine</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Albiomin | Albumin | Albumin Human Grifols | Albumin Human Immuno | Albumin Human Octapharma | Albunorm | Alburex | Human Albumin | Plasbumin | Uman albumin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Albiomin | Albumax | Albumina humana | Albumina humana grifols | Albumina serica humana normal | Albuminar | Alburex | Beribumin | Blaubimax | Octalbin | Plasbumin | Uman albumin | Vialebex</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Albuman | Albumin | Albumin csl | Flexbumin | Human albumin baxalta</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Vialebex</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Albumina humana | Albutein</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Albumin prepared from human plasma | Albuminar | Alburaas | Ao da | Ao ke te fa ma | Bei lin | Human Albumin | Human albumin-Biotest | Plasbumin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Albuman berna | Albumina humana | Alburex | Albutein | Blaubimax | Buminate | Flexbumin | Human Albumin | Seralbumin | Uman albumin | Vialebex | Zenalb</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Albumin | Albumin lidsky | Albunorm | Alburex | Albutein | Flexbumin | Human Albumin | Human albumin baxter</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Albiomin | Albumine Lfb | Albunorm | Alburex | Albutein | Flexbumin | Human Albumin | Human albumin baxter | Human albumin immuno | Humanalbumin | Normal serum</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Albuman | Albumina humana | Albutein | Seralbumin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Albuman | Albumina humana | Albunorm | Alburx</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Albumin | Albunorm | Flexbumin | Human Albumin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Albapure | Albumin-GCPD | Albuminar | Albuminativ | Albunorm | Alburaas | Albutein | Buminate | Cealb | Human Albumin | Human albumin octapharma | Plasbumin | Vialebex | Zenalb</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Albiomin | Albumina humana | Albumina Humana Behring | Albumina humana grifols | Albumina humana kedrion | Albunorm | Albuplan | Alburex | Flexbumin | Octalbin | Plasbumin</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Albunorm</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Albumin | Albumin baxter | Albuminativ | Albunorm | Alburex | Albutein | Flexbumin | Octalbin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Albumine baxter | Albumine Humaine | Albumine humaine baxter | Albunorm | Alburex | Flexbumin | Octalbine | Vialebex | Ydralbum</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Albunorm | Alburex | Albutein | Flexbumin | Human Albumin | Human albumin grifols | Octalbin | Zenalb | Zenbumin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Albiomin | Albuman | Albuminativ | Albumine Lfb | Alburex | Flexbumin | Human Albumin | Human albumin kedrion | Human albumin zlb | Human albumin/baxalta | Human albumin/grifols | Plasbumin | Zenalb</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Albumex | Albutein | Buminate | Gaipharm albumin | Human Albumin | Human albumin biotest | Kamapharm albumin human | Normal serum album | Plasbumin | Uman albumin | Vialebex</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Albumin (ljudski) 20% | Albumin ljudski 50 g/l | Human Albumin 5% Octapharma</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Albunorm | Alburex | Human Albumin | Human albumin kedrion | Human albumin octa | Plazmaprotein</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Albapure | Albuminar | Albunorm | Alburaas | Albutein | Cealb | Farmin | Human albumin 20% behring | Human albumin grifols | Octalbin | Plasbumin | Robumin | Zenalb</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Albuminativ | Albunorm | Flexbumin | Human albumin baxalta</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Human Albumin | Kamapharm albumin human</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alba | Albudac | Albukind | Albull | Albumed | Albumin | Albupan | Albuprime | Alburel | Alburel t | Albuspey | Albutein | Albuzest | Buminate | Flexbumin | Human Albumin | Human albumin grifols | Plasvex | Verbumin | Volumin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Albiomin | Albital | Albuman berna | Albumeon | Albumina grifols | Albumina lfb | Albumina Uman Kabi | Albumina umana | Albumina Umana Con | Albumina umana mf | Albunorm | Alburex | Albutein | Flexbumin | Haimalbumin | Octalbin | Uman albumin</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Albuman</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Albumin baxter | Albumin Behring | Albumin benesis | Albumin cutter | Albumin kaketsuken | Albumin Mitsubishi | Albuminar | Buminate | Human serum albumin | Kenketu albumin | Medway | Sekijuji albumin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Albumin gcc | Alburel</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Albumin | Gcc albumin | Sk albumin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Albuman | Alburex | Human Albumin | Human albumin csl behring | Plasbumin | Uman albumin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Albuman | Albutein | Human Albumin | Vialebex | Ydralbum</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Albumin | Albumin baxter | Albumin lidsky | Albumin Placentary | Albunorm | Cilveka albumina | Flexbumin | Human Albumin | Human albumin biotest | Human albumin csl behring | Spr | Zmogaus albuminas NKC</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Albumin | Albumin lidsky | Albumin Placentary | Albunorm | Cilveka albumina | Human Albumin | Human albumin csl behring | Spr</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Albumine Humaine | Albumine Human | Albunorm | Vialebex</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Albumar | Albumina | Albumina humana | Albumina Humana Behring | Albumina humana grifols | Albuminar | Albunate | Albutein | Flexbumin | Hi bumin | Kedrialb | Octalbin | Probialbumin | Seralbumin | Seroalbumina | Seroalbumina gi ce | Seroalbumina Humana | Seroalbumina Loeffler | Vanderbumin | Zenalb</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Albapure | Albuman berna | Albumin-kgcc | Albunorm | Alburx | Albutein | Buminate | Human Albumin | Human albumin behring | Plasbumin | Zenalb</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Albuman | Albunorm | Alburex | Cealb | Flexbumin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Albumin baxter | Albumin Octapharma | Albunorm | Alburex | Flexbumin | Human albumin biotest</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Acebumin | Albuman | Albumina humana | Albumina humana Octapharma | Alburex 20 | Seralbumin-25</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Albuman | Albumax | Albumeon | Albunorm | Alburel | Alburx | Albutein | Buminate | Flexbumin | Human albumin behring | Plasbumin | Plasbutein | Rescuerel | Zenalb</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Albuman | Albumeon | Albumin | Human Albumin | Plasbumin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Albumin human salzarm | Albumin ludzka | Albumina ludzka | Albunorm | Alburex | Flexbumin | Fortalbia | Human Albumin | Uman albumin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Albuked | Albumin-zlb | Albuminar | Albutein | Buminate | Flexbumin | Plasbumin | Plasbumin-5 Low Albumin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Albumina humana baxter | Albumina Humana Behring | Albumina humana grifols | Albumina humana kedrion | Albumina humana Octapharma | Albunorm | Alburex</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Albiomin | Albumin gcc | Albumina humana | Albumina humana blausiegel | Albumina humana duncan | Albumina humana eron | Albumina humana grifols | Albumina humana nortelab | Albumina humana quimfa | Albumina humana rhedquin | Albunorm | Alburel | Alburx | Kedrion Uman Albumin | Totalbumina</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Human Albumin Behring | Human Albumin Biotest</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Albiomin | Albumeon | Albumina umana baxter | Albumina umana grifols | Albumina umana kedrion | Albunorm | Alburex | Human Albumin | Vialebex</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Albiomin | Albumen | Albumin | Albumin Donor | Albumin Human Biotest | Albumin human dess | Albumin Placentary | Alburex | Human Albumin | Human albumin biotest | Plasbumin | Uman albumin | Zenalb</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Alburex | Albutein | Flexbumin | Human Albumin | Human albumin grifols | Plasbumin | Zenalb</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Albumer | Albumin | Albumin baxter | Albumin Behring | Albumin Hemasure | Albumin Immuno | Albumin Octapharma | Albuminar | Albuminativ | Albunorm | Alburex | Albutein | Flexbumin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Albutein | Buminate | Human Albumin | Zenalb Human Albumin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Albumin Humani | Flexbumin | Humani albumin csl behring</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Albumin | Albumin Human Lidsky | Albumin lidsky | Albunorm | Alburex | Flexbumin | Human albumin csl behring</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Albuman berna | Albumin 20 trcs | Albumin Octapharma | Albumin-kgcc | Albuminar | Alburaas | Albutein | Buminate | Flexbumin | Human Albumin | Human albumin 20% behring | Human albumin grifols | Human serum albumin | Kamapharm albumin (human) | Zenalb</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Albiomin | Albumin | Albumine | Albumine Humaine | Albunorm | Vialebex</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Alba | Albiomin | Albuman | Albumin | Albumin Hemasure | Albuminar | Buminate | Cealb | Flexbumin | Human Albumin | Plasbumin | Vialebex | Zenalb</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Albapure | Albuman berna | Albuminar | Albunorm | Albutein | Buminate albumin | Flexbumin | Human Albumin | Plasbumin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Albumin | Albumin Donor | Albumin Placentary | Albuminum human | Albunorm | Albuven | Flexbumin | Human Albumin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Albunorm</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Albuman | Albumina gcc | Albumina humana | Albunorm | Blaubimax | Seralbumin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Albumina humana</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Albusol</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Alburel</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-22980594">
<a name="22980594"></a>Abd Elaal MM, Zaghloul SG, Bakr HG, et al. Evaluation of different therapeutic approaches for spontaneous bacterial peritonitis. <i>Arab J Gastroenterol</i>. 2012;13(2):65-70. doi:10.1016/j.ajg.2012.06.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/22980594/pubmed" id="22980594" target="_blank">22980594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33067334">
<a name="33067334"></a>Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. <i>Gut</i>. 2021;70(1):9-29. doi:10.1136/gutjnl-2020-321790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/33067334/pubmed" id="33067334" target="_blank">33067334</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Albuked 5 (albumin [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics LLC; August 2020.</div>
</li>
<li>
<div class="reference">
                  Albuked 20 (albumin [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics LLC; August 2020.</div>
</li>
<li>
<div class="reference">
                  Albuked 25 (albumin [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics LLC; August 2020.</div>
</li>
<li>
<div class="reference">
                  Albuminex 25% (albumin [human]) [prescribing information]. Durham, NC: Bio Products Laboratory; received February 2019.</div>
</li>
<li>
<div class="reference">
                  Albuminex 5% (albumin [human]) [prescribing information]. Durham, NC: Bio Products Laboratory; August 2018.</div>
</li>
<li>
<div class="reference">
                  AlbuRx 5 (albumin [human]) [prescribing information]. Kankakee, IL: CSL Behring LLC; July 2020.</div>
</li>
<li>
<div class="reference">
                  Albutein (albumin) [prescribing information]. Los Angeles, CA: Grifols Biologicals Inc; July 2021.</div>
</li>
<li>
<div class="reference">
                  Albutein 5 (albumin [human]) [prescribing information]. Los Angeles, CA: Grifols Biologicals LLC; June 2018.</div>
</li>
<li>
<div class="reference">
                  Albutein 20 (albumin [human]) [prescribing information]. Los Angeles, CA: Grifols Biologicals LLC; June 2018.</div>
</li>
<li>
<div class="reference">
                  Albutein 25 (albumin [human]) [prescribing information]. Clayton, NC: Grifols Therapeutics Inc; August 2015.</div>
</li>
<li>
<div class="reference">
                  Albutein 25 (albumin [human]) [prescribing information]. Los Angeles, CA: Grifols Biologicals LLC; June 2018.</div>
</li>
<li>
<div class="reference">
                  Albutein FlexBag 25% (albumin [human]) [prescribing information]. Los Angeles, CA: Grifols Biologicals LLC; August 2021.</div>
</li>
<li>
<div class="reference">
                  Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793. To be codified at 21 CFR §201.323.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15563641">
<a name="15563641"></a>American Thoracic Society (ATS). Evidence-Based Colloid Use in the Critically Ill: American Thoracic Society Consensus Statement. <i>Am J Respir Crit Care Med</i>. 2004;170(11):1247-1259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/15563641/pubmed" id="15563641" target="_blank">15563641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10347109">
<a name="10347109"></a>Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. <i>Hepatology</i>. 1999;29(6):1690-1697. doi:10.1002/hep.510290629<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/10347109/pubmed" id="10347109" target="_blank">10347109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.1">
<a name="Expert.1"></a>Based on expert opinion.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14585874">
<a name="14585874"></a>Belver J, Muñoz EA, Ballesteros A, et al. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. <i>Hum Reprod</i>. 2003;18(11):2283-2288.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/14585874/pubmed" id="14585874" target="_blank">14585874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22095893">
<a name="22095893"></a>Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. <i>Hepatology</i>. 2012;55(4):1172-1181.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/22095893/pubmed" id="22095893" target="_blank">22095893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26896734">
<a name="26896734"></a>Boyer TD, Sanyal AJ, Wong F, et al; REVERSE Study Investigators. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. <i>Gastroenterology</i>. 2016;150(7):1579-1589.e2. doi:10.1053/j.gastro.2016.02.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/26896734/pubmed" id="26896734" target="_blank">26896734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19325359">
<a name="19325359"></a>Brierley J, Carcillo JA, Choong K, et al. Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update from the American College of Critical Care Medicine. <i>Crit Care Med</i>. 2009;37(2):666-688.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/19325359/pubmed" id="19325359" target="_blank">19325359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16215351">
<a name="16215351"></a>Budev MM, Arroliga AC, Falcone T. Ovarian hyperstimulation syndrome. <i>Crit Care Med</i>. 2005;33(10)(suppl):S301-S306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/16215351/pubmed" id="16215351" target="_blank">16215351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26820615">
<a name="26820615"></a>Caraceni P, Angeli P, Prati D, et al; Italian Association for the Study of the Liver (AISF); Italian Society of Transfusion Medicine and Immunohaematology (SIMTI). AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis. <i>Blood Transfus</i>. 2016;14(1):8-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/26820615/pubmed" id="26820615" target="_blank">26820615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25644760">
<a name="25644760"></a>Cavallin M, Kamath PS, Merli M, et al; Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. <i>Hepatology</i>. 2015;62(2):567-574. doi:10.1002/hep.27709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/25644760/pubmed" id="25644760" target="_blank">25644760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26659927">
<a name="26659927"></a>Cavallin M, Piano S, Romano A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. <i>Hepatology</i>. 2016;63(3):983-992.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/26659927/pubmed" id="26659927" target="_blank">26659927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10079061">
<a name="10079061"></a>Centers for Disease Control and Prevention. Hemolysis Associated With 25% Human Albumin Diluted With Sterile Water - United States, 1994-1998. <i>MMWR</i>. 1999;48(8):157-159. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00056596.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00056596.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/10079061/pubmed" id="10079061" target="_blank">10079061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33657293">
<a name="33657293"></a>China L, Freemantle N, Forrest E, et al; ATTIRE Trial Investigators. A randomized trial of albumin infusions in hospitalized patients with cirrhosis. <i>N Engl J Med</i>. 2021;384(9):808-817. doi:10.1056/NEJMoa2022166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/33657293/pubmed" id="33657293" target="_blank">33657293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cloherty.1">
<a name="Cloherty.1"></a>Cloherty JP, Eichenwald EC, Stark AR, eds. <i>Manual of Neonatal Care</i>. 7th ed. Lippincott Williams &amp; Wilkins; 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23353941">
<a name="23353941"></a>Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. <i>Crit Care Med</i>. 2013;41(2):580-637.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/23353941/pubmed" id="23353941" target="_blank">23353941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eichenwald.1">
<a name="Eichenwald.1"></a>Eichenwald EC, ed. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th ed. Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34276366">
<a name="34276366"></a>El-Desoki Mahmoud EI, Abdelaziz DH, Abd-Elsalam S, Mansour NO. Norepinephrine is more effective than midodrine/octreotide in patients with hepatorenal syndrome-acute kidney injury: a randomized controlled trial. <i>Front Pharmacol</i>. 2021;12:675948. doi:10.3389/fphar.2021.675948<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/34276366/pubmed" id="34276366" target="_blank">34276366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29653741">
<a name="29653741"></a>European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. <i>J Hepatol</i>. 2018;69(2):406-460. doi:10.1016/j.jhep.2018.03.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/29653741/pubmed" id="29653741" target="_blank">29653741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34605781">
<a name="34605781"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. <i>Crit Care Med</i>. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/34605781/pubmed" id="34605781" target="_blank">34605781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15163774">
<a name="15163774"></a>Finfer S, Bellomo R, Boyce N, et al. A Comparison of Albumin and Saline for Fluid Resuscitation in the Intensive Care Unit. SAFE Study Investigators. <i>N Engl J Med</i>. 2004;350(22):2247-2256.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/15163774/pubmed" id="15163774" target="_blank">15163774</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Flexbumin 5% (albumin human) [prescribing information]. Lexington, MA: Baxalta US Inc; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Flexbumin25.1">
<a name="Flexbumin25.1"></a>Flexbumin 25% (albumin human, USP) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21069691">
<a name="21069691"></a>Fortin PM, Bassett K, Musini VM. Human albumin for intradialytic hypotension in haemodialysis patients. <i>Cochrane Database Syst Rev.</i> 2010;(11):CD006758.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/21069691/pubmed" id="21069691" target="_blank">21069691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17680193">
<a name="17680193"></a>Fujita A, Kitayama M, Hirota K. Anaphylactoid shock in a patient following 5% human serum albumin infusion during off-pump coronary artery bypass grafting. <i>J Anesth</i>. 2007;21(3):396-398. doi:10.1007/s00540-007-0512-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/17680193/pubmed" id="17680193" target="_blank">17680193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21464748">
<a name="21464748"></a>Giefer MJ, Murray KF, Colletti RB. Pathophysiology, diagnosis, and management of pediatric ascites. <i>J Pediatr Gastroenterol Nutr</i>. 2011;52(5):503-513.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/21464748/pubmed" id="21464748" target="_blank">21464748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19651590">
<a name="19651590"></a>Gipson DS, Massengill SF, Yao L, et al. Management of childhood onset nephrotic syndrome. <i>Pediatrics</i>. 2009;124(2):747-757.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/19651590/pubmed" id="19651590" target="_blank">19651590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31258917">
<a name="31258917"></a>Griffiths MJD, McAuley DF, Perkins GD, et al. Guidelines on the management of acute respiratory distress syndrome. <i>BMJ Open Respir Res</i>. 2019;6(1):e000420. doi:10.1136/bmjresp-2019-000420<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/31258917/pubmed" id="31258917" target="_blank">31258917</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Human albumin 25% [prescribing information]. Research Triangle Park, NC: Grifols USA; April 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20173327">
<a name="20173327"></a>Jee BC, Suh CS, Kim YB, et al. Administration of intravenous albumin around the time of oocyte retrieval reduces pregnancy rate without preventing ovarian hyperstimulation syndrome: a systematic review and meta-analysis. <i>Gynecol Obstet Invest</i>. 2010;70(1):47-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/20173327/pubmed" id="20173327" target="_blank">20173327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956231">
<a name="20956231"></a>Kattwinkel J, Perlman JM, Aziz K, et al. Part 15: neonatal resuscitation: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2010;122(18)(suppl 3):S909-S919.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/20956231/pubmed" id="20956231" target="_blank">20956231</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kedbumin (albumin human) [prescribing information]. Fort Lee, NJ: Kedrion Biopharma Inc; May 2016.</div>
</li>
<li>
<div class="reference">
                  Kedbumin (albumin) [prescribing information]. Fort Lee, NJ: Kedrion Biopharma Inc; June 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2597561">
<a name="2597561"></a>Kelly AT, Short BL, Ranis TC, May JC, Progar JJ. Aluminum toxicity and albumin. <i>ASAIO Trans</i>. 1989;35(3):674-676.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/2597561/pubmed" id="2597561" target="_blank">2597561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956230">
<a name="20956230"></a>Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2010;122(18)(suppl 3):S876-S908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/20956230/pubmed" id="20956230" target="_blank">20956230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14747397">
<a name="14747397"></a>Knoll GA, Grabowski JA, Dervin GF, et al. A randomized, controlled trial of albumin versus saline for the treatment of intradialytic hypotension. <i>J Am Soc Nephrol</i>. 2004;15(2):487-492.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/14747397/pubmed" id="14747397" target="_blank">14747397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11593116">
<a name="11593116"></a>Kramer RE, Sokol RJ, Yerushalmi B, et al. Large-volume paracentesis in the management of ascites in children.<i> J Pediatr Gastroenterol Nutr</i>. 2001;33(3):245-249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/11593116/pubmed" id="11593116" target="_blank">11593116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33837624">
<a name="33837624"></a>Kwong A, Kim WR, Kwo PY, Wang U, Cheng X. Feasibility and effectiveness of norepinephrine outside the intensive care setting for treatment of hepatorenal syndrome. <i>Liver Transpl</i>. 2021;27(8):1095-1105. doi:10.1002/lt.26065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/33837624/pubmed" id="33837624" target="_blank">33837624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26325252">
<a name="26325252"></a>Lane ER, Hsu EK, Murray KF. Management of ascites in children. <i>Expert Rev Gastroenterol Hepatol</i>. 2015;9(10):1281-1292.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/26325252/pubmed" id="26325252" target="_blank">26325252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19657486">
<a name="19657486"></a>Liumbruno GM, Bennardello F, Lattanzio A, Piccoli P, Rossettias G; Italian Society of Transfusion Medicine and Immunohaematology (SIMTI). Recommendations for the use of albumin and immunoglobulins. <i>Blood Transfus</i>. 2009;7(3):216-34. doi:10.2450/2009.0094-09<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/19657486/pubmed" id="19657486" target="_blank">19657486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17989698">
<a name="17989698"></a>Lynch SK, Mullett MD, Graeber JE, et al. A Comparison of Albumin-Bolus Therapy Versus Normal Saline-Bolus Therapy for Hypotension in Neonates. <i>J Perinatol</i>. 2008;28(1):29-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/17989698/pubmed" id="17989698" target="_blank">17989698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21615299">
<a name="21615299"></a>Maitland K, Kiguli S, Opoka RO, et al. Mortality After Fluid Bolus in African Children With Severe Infection. <i>N Engl J Med</i>. 2011;364(26):2483-2495.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/21615299/pubmed" id="21615299" target="_blank">21615299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12394941">
<a name="12394941"></a>Martin GS, Mangialardi RJ, Wheeler AP, Dupont WD, Morris JA, Bernard GR. Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury.<i> Crit Care Med.</i> 2002;30(10):2175-2182. doi:10.1097/00003246-200210000-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/12394941/pubmed" id="12394941" target="_blank">12394941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16096441">
<a name="16096441"></a>Martin GS, Moss M, Wheeler AP, Mealer M, Morris JA, Bernard GR. A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. <i>Crit Care Med</i>. 2005;33(8):1681-1687. doi:10.1097/01.ccm.0000171539.47006.02<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/16096441/pubmed" id="16096441" target="_blank">16096441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18471512">
<a name="18471512"></a>Martín-Llahí M, Pépin MN, Guevara M, et al; TAHRS Investigators. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. <i>Gastroenterology</i>. 2008;134(5):1352-1359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/18471512/pubmed" id="18471512" target="_blank">18471512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30785101">
<a name="30785101"></a>Moreno Lozano L, Galindo Bonilla P, Borja Segade J, Extremera Ortega A, Gómez Torrijos E, García Rodríguez R. Human serum albumin induced anaphylaxis in a patient with good tolerance to human plasma. <i>J Investig Allergol Clin Immunol</i>. 2019;29(1):51-53. doi:10.18176/jiaci.0325<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/30785101/pubmed" id="30785101" target="_blank">30785101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17761591">
<a name="17761591"></a>Myburgh J, Cooper DJ, Finfer S, et al; SAFE Study Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group; Australian Red Cross Blood Service; George Institute for International Health. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. <i>N Engl J Med</i>. 2007;357(9):874-884. doi:10.1056/NEJMoa067514<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/17761591/pubmed" id="17761591" target="_blank">17761591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13679934">
<a name="13679934"></a>Oca MJ, Nelson M, Donn SM. Randomized trial of normal saline versus 5% albumin for the treatment of neonatal hypotension. <i>J Perinatol</i>. 2003;23(6):473-476.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/13679934/pubmed" id="13679934" target="_blank">13679934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12297842">
<a name="12297842"></a>Ortega R, Ginès P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. <i>Hepatology</i>. 2002;36(4, pt 1):941-948.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/12297842/pubmed" id="12297842" target="_blank">12297842</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Plasbumin (albumin) [prescribing information]. Research Triangle Park, NC: Talecris Biotherapeutics Inc; April 2010.</div>
</li>
<li>
<div class="reference">
                  Plasbumin-5 (albumin [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics; August 2020.</div>
</li>
<li>
<div class="reference">
                  Plasbumin-5 (albumin [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics; September 2017.</div>
</li>
<li>
<div class="reference">
                  Plasbumin-20 (albumin [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics LLC; August 2020.</div>
</li>
<li>
<div class="reference">
                  Plasbumin-25 (albumin [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics LLC; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27678032">
<a name="27678032"></a>Practice Committee of the American Society for Reproductive Medicine (ASRM). Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. <i>Fertil Steril</i>. 2016;106(7):1634-1647. doi:10.1016/j.fertnstert.2016.08.048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/27678032/pubmed" id="27678032" target="_blank">27678032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling,</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26390995">
<a name="26390995"></a>Ritzenthaler T, Grousson S, Dailler F. Hyperchloremic metabolic acidosis following plasma exchange during myasthenia gravis crisis. <i>J Clin Apher</i>. 2016;31(5):479-480. doi:10.1002/jca.21432<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/26390995/pubmed" id="26390995" target="_blank">26390995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9585860">
<a name="9585860"></a>Roberts JS and Bratton SL, Colloid volume expanders. Problems, pitfalls, and possibilities. <i>Drugs.</i> 1998;55(5):621-630.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/9585860/pubmed" id="9585860" target="_blank">9585860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12921248">
<a name="12921248"></a>Robinson RF, Nahata MC, Mahan JD, Batisky DL. Management of nephrotic syndrome in children. <i>Pharmacotherapy</i>. 2003;23(8):1021-1036.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/12921248/pubmed" id="12921248" target="_blank">12921248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16552809">
<a name="16552809"></a>Romanelli RG1, La Villa G, Barletta G. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. <i>World J Gastroenterol</i>. 2006;12(9):1403-1407.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/16552809/pubmed" id="16552809" target="_blank">16552809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Runyon.2">
<a name="Runyon.2"></a>Runyon BA. Hepatorenal syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 4, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Runyon.3">
<a name="Runyon.3"></a>Runyon BA. Spontaneous bacterial peritonitis in adults: treatment and prophylaxis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 20, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23463403">
<a name="23463403"></a>Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. <i>Hepatology</i>. 2013;57(4):1651-1653. doi:10.1002/hep.26359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/23463403/pubmed" id="23463403" target="_blank">23463403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12734047">
<a name="12734047"></a>Sabri M, Saps M, Peters JM. Pathophysiology and management of pediatric ascites.<i> Curr Gastroenterol Rep</i>. 2003;5(3):240-246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/12734047/pubmed" id="12734047" target="_blank">12734047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23178229">
<a name="23178229"></a>Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. <i>Clin Gastroenterol Hepatol</i>. 2013;11(2):123-130. doi:10.1016/j.cgh.2012.11.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/23178229/pubmed" id="23178229" target="_blank">23178229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29080733">
<a name="29080733"></a>Shmorgun D, Claman P. No-268-the diagnosis and management of ovarian hyperstimulation syndrome.<i> J Obstet Gynaecol Can</i>. 2017;39(11):e479-e486. doi:10.1016/j.jogc.2017.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/29080733/pubmed" id="29080733" target="_blank">29080733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17369392">
<a name="17369392"></a>Sigal SH, Stanca CM, Fernandez J, Arroyo V, Navasa M. Restricted use of albumin for spontaneous bacterial peritonitis. <i>Gut</i>. 2007;56(4):597-599. doi:10.1136/gut.2006.113050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/17369392/pubmed" id="17369392" target="_blank">17369392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10432325">
<a name="10432325"></a>Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. <i>N Engl J Med</i>. 1999;341(6):403-409. doi:10.1056/NEJM199908053410603<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/10432325/pubmed" id="10432325" target="_blank">10432325</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  UHC Clinical Practice Advancement Center. Technology assessment: albumin, nonprotein colloid, and crystalloid solutions. Oak Brook, IL: University Health System Consortium; May 2000.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24405693">
<a name="24405693"></a>Uhlig C, Silva PL, Deckert S, Schmitt J, de Abreu MG. Albumin versus crystalloid solutions in patients with the acute respiratory distress syndrome: a systematic review and meta-analysis.<i> Crit Care.</i> 2014;18(1):R10. doi:10.1186/cc13187<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/24405693/pubmed" id="24405693" target="_blank">24405693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7848020">
<a name="7848020"></a>Vermeulen LC Jr, Ratko TA, Erstad BL, et al. A paradigm for consensus. The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. <i>Arch Intern Med</i>. 1995;155(4):373-379.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/7848020/pubmed" id="7848020" target="_blank">7848020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20579987">
<a name="20579987"></a>Venetis CA, Kolibianakis EM, Toulis KA, Goulis DG, Papadimas I, Tarlatzis BC. Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis. <i>Fertil Steril</i>. 2011;95(1):188-196.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/20579987/pubmed" id="20579987" target="_blank">20579987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30758852">
<a name="30758852"></a>Wang KY, Friedman DF, DaVeiga SP. Immediate hypersensitivity reaction to human serum albumin in a child undergoing plasmapheresis. <i>Transfusion</i>. 2019;59(6):1921-1923. doi:10.1111/trf.15194<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/30758852/pubmed" id="30758852" target="_blank">30758852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33657294">
<a name="33657294"></a>Wong F, Pappas SC, Curry MP, et al; CONFIRM Study Investigators. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. <i>N Engl J Med</i>. 2021;384(9):818-828. doi:10.1056/NEJMoa2008290<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/33657294/pubmed" id="33657294" target="_blank">33657294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26473001">
<a name="26473001"></a>Wyckoff MH, Aziz K, Escobedo MB, et al. Part 13: neonatal resuscitation: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2015;132(18)(suppl 2):S543-S560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/26473001/pubmed" id="26473001" target="_blank">26473001</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9376 Version 320.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
